Addex Therapeutics: Implications of Transporter Regulatory Themes in Drug Development
Sonia Poli, VP for Non Clinical Development at Addex Therapeutics, a small biotech built in Geneva explains how the new FDA and EMA guidelines will impact their business. She looks at the daily challenges they are faced with and stresses the importance of having highly valuated assays which will translate into clinical data.
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.